These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 18537758)
21. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. Chan DC; Barrett PH; Watts GF Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):369-85. PubMed ID: 24840265 [TBL] [Abstract][Full Text] [Related]
22. Fibrates after the FIELD study: Some answers, more questions. Wierzbicki AS Diab Vasc Dis Res; 2006 Dec; 3(3):166-71. PubMed ID: 17160911 [TBL] [Abstract][Full Text] [Related]
23. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
24. Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression. Negi S; Ballantyne CM J Clin Lipidol; 2010; 4(5):365-70. PubMed ID: 21122680 [TBL] [Abstract][Full Text] [Related]
25. Practical recommendations for the management of hyperlipidemia. Fischer S; Schatz U; Julius U Atheroscler Suppl; 2015 May; 18():194-8. PubMed ID: 25936326 [TBL] [Abstract][Full Text] [Related]
26. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs. Kones R; Rumana U Drugs; 2015 Jul; 75(11):1201-28. PubMed ID: 26169307 [TBL] [Abstract][Full Text] [Related]
27. Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol. Szapary PO; Rader DJ Curr Opin Pharmacol; 2001 Apr; 1(2):113-20. PubMed ID: 11714084 [TBL] [Abstract][Full Text] [Related]
28. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Borow KM; Nelson JR; Mason RP Atherosclerosis; 2015 Sep; 242(1):357-66. PubMed ID: 26253795 [TBL] [Abstract][Full Text] [Related]
29. Hypertriglyceridemia and cardiovascular risk reduction. Jacobson TA; Miller M; Schaefer EJ Clin Ther; 2007 May; 29(5):763-777. PubMed ID: 17697898 [TBL] [Abstract][Full Text] [Related]
30. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404 [TBL] [Abstract][Full Text] [Related]
31. Lipid Lowering Therapy for Atherosclerotic Cardiovascular Disease: It Is Not So Simple. Vincent J Clin Pharmacol Ther; 2018 Aug; 104(2):220-224. PubMed ID: 30117592 [TBL] [Abstract][Full Text] [Related]
32. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582 [TBL] [Abstract][Full Text] [Related]
33. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
34. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy? Robins SJ Curr Opin Lipidol; 2003 Dec; 14(6):575-83. PubMed ID: 14624134 [TBL] [Abstract][Full Text] [Related]